Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.
Also called NCT01912534
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 211 participants
- Registry
-
NCT01912534
-
- Other papers using this trial's data
- Body Mass Index, Valsartan, and Myocardial Remodeling in Early-Stage Hypertrophic Cardiomyopathy: A Secondary Analysis of the Randomized VANISH Trial
- Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial
- Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial
- Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial
- Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance Substudy
- Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT01912534. Randomized; triple masking; primary purpose treatment. Start 2014-03 (actual); primary completion 2019-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
- Acronym
- VANISH
- Condition
- Hypertrophic Cardiomyopathy
- Intervention (Drug)
- Valsartan
- Intervention (Drug)
- Placebo
- Lead sponsor
- Carelon Research
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct01912534- Content hash
fd59c085a8cb71dc11ee44c2913e07af32e0e1e015efc1b99ae04463160b0b1d